FDA Approves Rucaparib for Adult Patients with BRCA+ mCRPC

The FDA approved rucaparib for the treatment of adult patients with a deleterious BRCA mutation-associated metastatic castration-resistant prostate cancer.

Source: CancerNetwork - May 15, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news